Hexarelin protects heart cells from angiotensin II-induced hypertrophy by enhancing autophagy via mTOR suppression.
Background
Cardiac hypertrophy, an enlargement of heart muscle cells, is a common response to chronic pressure overload (like hypertension) and a major risk factor for heart failure. A key pathological driver of this process is angiotensin-II (Ang-II), which promotes cell growth, oxidative stress, and apoptosis. While managing hypertrophy is critical, existing therapies often have limitations. Autophagy, the cellular process of degrading and recycling damaged components, is known to be cardioprotective. Hexarelin, a synthetic growth hormone-releasing peptide, has demonstrated protective effects on the heart, but its specific mechanism in the context of hypertrophy was unclear. This study investigates whether hexarelin's benefits are mediated by modulating the autophagy pathway, particularly its upstream regulator, mTOR.
Study Design
This was an in vitro study using the H9C2 rat cardiomyocyte cell line. To induce a hypertrophic state, cells were treated with angiotensin-II (Ang-II). Researchers then treated these cells with hexarelin. Autophagy was measured using multiple methods: immunofluorescence for LC3, monodansylcadaverine (MDC) staining for autophagic vacuole visualization, and Cyto-ID staining for autophagic flux. Molecular changes were assessed via Western blotting and qRT-PCR. Apoptosis was evaluated using flow cytometry and a TUNEL assay, while cell survival was measured by ATP content and a CCK-8 assay. Oxidative stress markers (MDA, SOD) were also analyzed.
Results
Treatment with angiotensin-II successfully induced cardiomyocyte hypertrophy, increased oxidative stress, triggered apoptosis, and reduced cell survival in H9C2 cells. The introduction of hexarelin significantly suppressed all of these pathological changes. Hexarelin treatment was shown to enhance autophagy in the hypertrophic cells. Critically, when this hexarelin-induced autophagy was blocked using the inhibitor 3-methyladenine (3MA), the anti-hypertrophic and protective effects of hexarelin were abolished. This confirmed that autophagy was essential for hexarelin's mechanism of action.
Conversely, stimulating autophagy directly with rapamycin mimicked hexarelin's effects, leading to reduced apoptosis, improved cell survival, and smaller cell size in the hypertrophic model. Mechanistically, hexarelin was found to regulate this process by inhibiting the phosphorylation of the
mammalian target of rapamycin (mTOR), a key upstream inhibitor of autophagy.
Key Findings
- Hexarelin significantly suppressed Angiotensin-II-induced cardiomyocyte hypertrophy, oxidative stress, and apoptosis.
- The anti-hypertrophic and pro-survival effects of hexarelin were abolished when autophagy was inhibited with 3-methyladenine (3MA).
- Stimulating autophagy with rapamycin replicated the protective effects of hexarelin, reducing cell size and apoptosis.
- Hexarelin enhanced autophagy by inhibiting the phosphorylation of the mTOR signaling pathway.
- Hexarelin treatment increased cell survival and ATP content in hypertrophic H9C2 cells.
Why It Matters
This research provides a specific molecular mechanism for hexarelin's known cardioprotective effects, linking it directly to the modulation of autophagy via the mTOR pathway. For researchers and biohackers exploring cardiac health protocols, this suggests hexarelin may be a powerful tool for mitigating cellular stress and damage associated with hypertrophy. The key takeaway is that hexarelin's benefit isn't just from GH release, but from direct cellular housekeeping improvements. This finding could influence how hexarelin is stacked, potentially pairing it with other compounds that support autophagy or avoiding those that inhibit it. Clinically, this is very early-stage in vitro work, far from a human protocol, but it solidifies the rationale for pursuing GHRPs as potential therapeutics for heart disease beyond their secretagogue function.
